[Immunoactive drugs in the combined modality therapy of patients with hypothyroidism].
Comparative studies into the clinico-immunologic status of patient with primary hypothyrosis have shown that the multimodality treatment including differentiated administration of immunoactive agents (glucocorticoids, splenin) promoted more well-defined normalization of cellular, humoral immunity and nonspecific defence as well as reduction or disappearance of the clinical disease manifestations as compared to patients who did not receive those drugs as part of the multimodality therapy. The use of glucocorticoids and splenin may be recommended as part of the multimodality treatment of patients suffering from primary hypothyrosis marked by pronounced disorders in the immune system.
Epishin
A V
AV
Grytsiv
V E
VE
Venger
E P
EP
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D000368:Aged; D000917:Antibody Formation / Q000187:drug effects; D001402:B-Lymphocytes / Q000187:drug effects; D003131:Combined Modality Therapy; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D007037:Hypothyroidism / Q000188:drug therapy*; D007111:Immunity, Cellular / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D013601:T-Lymphocytes / Q000187:drug effects; D013946:Thymopoietins / Q000627:therapeutic use*
D000276:Adjuvants, Immunologic; D005938:Glucocorticoids; D013946:Thymopoietins; C032841:thymopoietin III
Immunoaktivnye preparaty v kompleksnom lechenii bol'nykh gipotireozom.